CETA and Changes to Canada’s Pharmaceutical Patent Regime: Too Much or Not Enough IP?

The Conference Board of Canada, 23 pages, March 2014
Briefing by David Verbeeten
(You must be signed in and entitled to rate this report)
This briefing provides a clear description of Canada’s complex pharmaceutical patent regime, and determines the likely effects of the Comprehensive Economic and Trade Agreement on drug prices, manufacturing, and exports.

Document Highlights

Canada’s pharmaceutical patent regime is set to change as a result of the Comprehensive Economic and Trade Agreement (CETA). This accord, which represents Canada’s largest trade initiative since the North American Free Trade Agreement of the 1990s.

This briefing assesses the evidence to determine the likely effects of CETA on Canada’s innovation ecosystem, drug prices, manufacturing, and exports.

Given the evidence and the types of changes that the Canadian government is, and is not willing, to make, it is likely that CETA will improve Canada’s health innovation ecosystem, which could lead to social and economic value for Canadians. Indeed, the Canadian government has performed a fine balancing act, ensuring that the country’s intellectual property regime will remain distinctly Canadian, with a basic structure that aligns with global standards yet considers the domestic context.

Access document

(you will be asked to sign-in)

To see if you are entitled to get this research for free, take a minute and create a free e-Library account. This will let us determine if someone else at your organization has already purchased access to this material.
Learn more about the e-Library by watching our interactive video:

CETA and Changes to Canada’s Pharmaceutical Patent Regime: Too Much or Not Enough IP?Rating:5.000000 out of5based on1 reviews.